The multidisciplinary programs, combining scientists trained in cell biology, biochemistry, immunology, pharmacology, and viral oncology will evaluate the antineoplastic, immunomodulatory, and antiviral functions of human interferon. The human interferon system can provide a powerful tool for uncovering mechanisms of cellular transformation and proliferation of tumor cells. Our objectives include elucidating mechanisms whereby interferon can phenotypically correct tumor cells by forcing their entry into differentiation programs. Down-regulation or demotion of tumor cells via interferon should allow genetically defined progressions to occur, resulting in either terminal differentiation or cell quiescence. Interferon may play a role in normal development/ differentiation and unlock specific genes. To complement biological investigation, recombinant DNA technology will reveal those specific sets of genes whose expression is altered during differentiation and malignant transformation. The approach depends upon an in-depth study of interferon action at various levels of biological organization: in tissue culture and athymic mice and in patients with neoplastic disease. Also, new classes of interferon inducers have been structured to trigger the various forms of endogenous interferon without host toxicity. Mismatched analogs of rIn.rCn can strengthen immunological defense to tumor. Immunomodulatory studies of interferon and its inducers will encompass a broad range of projects from subcellular to organismic levels. Effects of interferon on lymphocyte functions, including natural killer cells and macrophage activity, should provide a firm clinical rationale for its improved use in pharmacological modulation of neoplasia. The antiproliferative limb of interferon action will be systematically determined following transplantation of human tumor cells, particularly those of epithelial origin, into athymic mice. Such an innovative and in-depth study brought about by a fully integrated approach will establish earlier diagnostic methods and new principles for effective biological therapy of cancer, thus resulting in more effective control and elimination of cancer cells in humans. (V)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA029545-06
Application #
3093295
Study Section
Cancer Special Program Advisory Committee (CAK)
Project Start
1981-06-01
Project End
1987-05-31
Budget Start
1986-06-01
Budget End
1987-05-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Hahnemann University
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19129
Suhadolnik, R J; Reichenbach, N L; Hitzges, P et al. (1994) Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 8:599-604
Gillespie, D; Hubbell, H R; Carter, W A et al. (1994) Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. In Vivo 8:375-81
Hubbell, H R; Kariko, K; Suhadolnik, R J et al. (1994) RNase L and increased endoribonuclease activities in the mononuclear cells of patients with chronic myelogenous leukemia. Anticancer Res 14:341-6
Suhadolnik, R J; Reichenbach, N L; Hitzges, P et al. (1994) Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 18 Suppl 1:S96-104
Hubbell, H R; Gibson, G D; Bigler, R D (1992) Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA. Cancer Immunol Immunother 34:259-64
Hubbell, H R; Vargas, H E; Tsujimoto, K L et al. (1992) Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. Cancer Immunol Immunother 35:151-7
Muller, W E; Weiler, B E; Charubala, R et al. (1991) Cordycepin analogues of 2',5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochemistry 30:2027-33
Hubbell, H R; Boyer, J E; Roane, P et al. (1991) Cyclic AMP mediates the direct antiproliferative action of mismatched double-stranded RNA. Proc Natl Acad Sci U S A 88:906-10
Hubbell, H R; Sheetz, P C; Iogal, S S et al. (1991) Heterogeneous nuclear RNA from hairy cell leukemia patients activates 2',5'-oligoadenylate synthetase. Anticancer Res 11:1927-32
Morgan, D A; Gumucio, D L; Brodsky, I (1991) Granulocyte-macrophage colony-stimulating factor-dependent growth and erythropoietin-induced differentiation of a human cell line MB-02. Blood 78:2860-71

Showing the most recent 10 out of 61 publications